Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test a new drug called MK-2206. This study is a phase II
study. In cancer studies, a phase II study is to find out what effects, good and/or bad, a
new treatment has against a certain type of cancer.
MK-2206 is an oral medication known as a targeted therapy. By attaching to the target, we
hope that MK-2206 may stop the cancer cells from further growth and dividing. This study will
help find out if MK-2206 is a helpful drug when taken in patients with neuroendocrine tumor.